1) CanniMed Therapeutics is an international, biopharmaceutical company and leader in the Canadian medical cannabis industry with pharmaceutical-grade products.
2) They have a 15-year history of growing medical cannabis and a first mover advantage in emerging international markets like Australia.
3) Recent results show strong revenue, volume, and EBITDA growth and they have expanded production capacity with government support. The Canadian and international medical cannabis markets provide significant opportunities.
This presentation discusses MedReleaf's forward-looking statements and non-IFRS measures, provides an overview of the company's operations and facilities, highlights its financial and operational performance to date, and outlines its growth strategies and milestones for the next 18 months. Key points include that MedReleaf has achieved over 80% market share in the Canadian medical cannabis market, has expanded production capacity through a new facility, and aims to leverage its expertise internationally and participate in the potential Canadian recreational cannabis market.
This presentation discusses MedReleaf's position as the leading Canadian medical cannabis producer. It highlights MedReleaf's quality assurance processes, patient-centric approach, analytical operations, and ongoing innovation in producing premium cannabis. MedReleaf also discusses its market leading position with 82% market share, low production costs of $1.49 per gram, and high adjusted product contribution margins of 19%. The presentation outlines MedReleaf's expansion plans and growth opportunities in medical, new products, recreational, and international markets.
CanniMed Therapeutics Inc. is a leader in the Canadian medical cannabis industry and the first mover in international markets. It has a 15-year history of growing pharmaceutical-grade cannabis and is well positioned for growth through new distribution channels in Canada, increasing production capacity, and pursuing exports to multiple countries. Recent developments include strong Q3 2017 results, entering Canada's first pharmacy distribution agreement, and commencing an expansion of its Cannabis Oils Facility.
This document summarizes an investor presentation for MedReleaf Corp.'s initial public offering. Key points include that MedReleaf is offering shares at $9.50-$10.50 per share to raise approximately $100 million Canadian dollars, which will be used to expand their existing cannabis production facility, develop new products, and for general corporate purposes. Investors are warned to consider the risks disclosed in the prospectus and that forward-looking statements are based on estimates and assumptions. The presentation highlights MedReleaf's current operational success, low production costs, high market share, and near-term expansion plans.
Canni med therapeutics inc management presentation - march 2017CannimedTherapeutics
CanniMed Therapeutics is a Canadian pharmaceutical company and leader in the medical cannabis industry with 15 years of experience culturing cannabis. It has a GMP-compliant production process with strict quality control and is conducting the first Health Canada approved Phase IIA clinical trial. CanniMed is focused on producing pharmaceutical-grade cannabis products and developing new delivery methods, such as cannabis oil gelcaps, to appeal to broader medical markets for pain treatment. It aims to address the large market for alternative chronic pain therapies and the needs of aging baby boomers.
MedReleaf is a Canadian licensed producer of medical cannabis with a market capitalization of $890 million. It has the largest market share of the Canadian medical cannabis market at 82%. The presentation discusses MedReleaf's strategy of focusing on quality, innovation, and profitability to establish itself as the standard in the medical cannabis industry. It highlights the company's expansion plans, new product development, and growth opportunities in medical cannabis in Canada and international markets.
CanniMed Therapeutics Inc. is a Canadian pharmaceutical company and leader in the medical cannabis industry with 15 years of experience cultivating cannabis. It has GMP-compliant production facilities and a clinical research program. CanniMed raised $69 million in its IPO to fund expansion and clinical trials to validate medical cannabis for pain relief. It focuses on pharmaceutical-grade products including cannabis oils to address the needs of the growing medical cannabis market and aging population seeking pain treatment alternatives.
Pathway Health is one of the largest providers of out-of-hospital pain management services in Canada. We own and operate nine community-based clinics across four provinces where our team of health professionals work together to help patients by using a variety of evidence-based approaches.
This presentation discusses MedReleaf's forward-looking statements and non-IFRS measures, provides an overview of the company's operations and facilities, highlights its financial and operational performance to date, and outlines its growth strategies and milestones for the next 18 months. Key points include that MedReleaf has achieved over 80% market share in the Canadian medical cannabis market, has expanded production capacity through a new facility, and aims to leverage its expertise internationally and participate in the potential Canadian recreational cannabis market.
This presentation discusses MedReleaf's position as the leading Canadian medical cannabis producer. It highlights MedReleaf's quality assurance processes, patient-centric approach, analytical operations, and ongoing innovation in producing premium cannabis. MedReleaf also discusses its market leading position with 82% market share, low production costs of $1.49 per gram, and high adjusted product contribution margins of 19%. The presentation outlines MedReleaf's expansion plans and growth opportunities in medical, new products, recreational, and international markets.
CanniMed Therapeutics Inc. is a leader in the Canadian medical cannabis industry and the first mover in international markets. It has a 15-year history of growing pharmaceutical-grade cannabis and is well positioned for growth through new distribution channels in Canada, increasing production capacity, and pursuing exports to multiple countries. Recent developments include strong Q3 2017 results, entering Canada's first pharmacy distribution agreement, and commencing an expansion of its Cannabis Oils Facility.
This document summarizes an investor presentation for MedReleaf Corp.'s initial public offering. Key points include that MedReleaf is offering shares at $9.50-$10.50 per share to raise approximately $100 million Canadian dollars, which will be used to expand their existing cannabis production facility, develop new products, and for general corporate purposes. Investors are warned to consider the risks disclosed in the prospectus and that forward-looking statements are based on estimates and assumptions. The presentation highlights MedReleaf's current operational success, low production costs, high market share, and near-term expansion plans.
Canni med therapeutics inc management presentation - march 2017CannimedTherapeutics
CanniMed Therapeutics is a Canadian pharmaceutical company and leader in the medical cannabis industry with 15 years of experience culturing cannabis. It has a GMP-compliant production process with strict quality control and is conducting the first Health Canada approved Phase IIA clinical trial. CanniMed is focused on producing pharmaceutical-grade cannabis products and developing new delivery methods, such as cannabis oil gelcaps, to appeal to broader medical markets for pain treatment. It aims to address the large market for alternative chronic pain therapies and the needs of aging baby boomers.
MedReleaf is a Canadian licensed producer of medical cannabis with a market capitalization of $890 million. It has the largest market share of the Canadian medical cannabis market at 82%. The presentation discusses MedReleaf's strategy of focusing on quality, innovation, and profitability to establish itself as the standard in the medical cannabis industry. It highlights the company's expansion plans, new product development, and growth opportunities in medical cannabis in Canada and international markets.
CanniMed Therapeutics Inc. is a Canadian pharmaceutical company and leader in the medical cannabis industry with 15 years of experience cultivating cannabis. It has GMP-compliant production facilities and a clinical research program. CanniMed raised $69 million in its IPO to fund expansion and clinical trials to validate medical cannabis for pain relief. It focuses on pharmaceutical-grade products including cannabis oils to address the needs of the growing medical cannabis market and aging population seeking pain treatment alternatives.
Pathway Health is one of the largest providers of out-of-hospital pain management services in Canada. We own and operate nine community-based clinics across four provinces where our team of health professionals work together to help patients by using a variety of evidence-based approaches.
The document is a corporate presentation for Zenabis Global Inc. that provides an overview of the company's history and operations. It notes that Zenabis was formed in January 2019 through the reverse takeover of Bevo Agro Inc. by Sun Pharm Investments Ltd. Bevo Agro had a successful 30+ year history of growing hundreds of unique crops at an industrial scale in British Columbia, with EBITDA growing at 20% annually from 2011 to 2018 and EBITDA margins of around 24% in 2018. The presentation contains standard disclaimer language about forward-looking statements and the purpose of the document being for information only.
We’re creating better everyday products that combine cutting-edge plant-based materials and the latest sustainable designs so you can look good AND feel good!
Aveda Transportation and Energy Services Inc. presented its corporate strategy and outlook in January 2017. The presentation discussed Aveda's history of growth through acquisitions and expansion across North America since 1994. It highlighted Aveda's leadership team and board of directors with extensive oilfield experience. The presentation also noted Aveda's track record of revenue and adjusted EBITDA growth despite a 40% decline in rig counts from 2015 to 2016, demonstrating resilience in the downturn.
Corporate presentation november 2016 finalcorpaveda2015
This corporate presentation provides an overview of Aveda Transportation and Energy Services Inc. It discusses Aveda's history of growth through acquisitions and expansion across North America. The presentation highlights Aveda's diversified revenue base across major oil basins in the US and Canada, as well as its blue chip customer base. It also summarizes Aveda's capitalization, balance sheet, and North American operations footprint.
This document contains an investor presentation for an organization providing chronic pain services and medical cannabis telehealth. It discusses the company's growth from $600k in 2018 revenue to $12.6 million in 2020, its network of 9 pain clinics across Canada, and plans for expansion. It also outlines the company's proprietary digital platform, pharmacy initiatives including pharmacist education and patient referrals, and financial overview showing its sources of revenue. The document contains numerous disclaimers regarding forward-looking statements and risks involved in the company's projections.
The Health & Wellness market in the UK was valued at £23bn in 2020, an increase from £20.5bn in 2015. Total healthcare, wellness and fitness spending in the UK reached £209bn in 2020. Pure Restore Health provides innovative treatments and therapies utilizing the latest healthcare technologies to help people feel their best by addressing issues like chronic pain, injury recovery, athletic performance and more.
Marel held a Capital Markets Day to provide an overview of the company and its strategy for delivering 12% annual revenue growth globally through digital and sustainable solutions. Marel aims to be a one-stop-shop across poultry, meat, and fish processing with standardized modular equipment, proprietary software, and digital solutions. The company's focus on innovation, excellence, and ESG/sustainability has supported over 20% average annual revenue growth since its 1992 listing.
This document provides an overview of Nobilis Health Corp., including:
- Nobilis operates surgical hospitals, ambulatory surgery centers (ASCs), and clinics across multiple states, utilizing a direct-to-consumer marketing model.
- Their growth strategy focuses on optimizing their case mix, acquiring additional facilities and service lines, and leveraging operational efficiencies through scale.
- Their unique marketing approach drives organic patient volume growth by targeting prospective patients and providing a superior experience for physicians and patients.
Marel Capital Markets Day 2021 - DigitalizationMarel
The document provides an overview of a presentation by Marel hf. on digitally transforming food processing. It includes disclaimers that no representations or warranties are given, information is subject to change, and forward-looking statements involve risks. Market and industry data is from Marel's internal research and estimates and has not been verified. The presentation does not constitute an offer to purchase securities.
Marel Capital Markets Day 2021 - Global-reachMarel
The document provides an overview and disclaimer for a presentation by Marel hf. It states that the purpose is to provide information about the company and its disclaimer notes that no representations are made about the accuracy or completeness of the information. It also says the information is based on current matters and is subject to change without notice. Finally, it notes the presentation does not constitute an offer to purchase securities and is not intended as investment advice.
Bragg Gaming Group is a next generation gaming group with cutting-edge technology, leading brands and world-class management expertise, developing into a global gaming force. Formed by a team of gaming industry experts, Bragg's main portfolio asset is ORYX Gaming, an innovative business-to-business gaming technology platform and casino content aggregator. Through this brand and targeted acquisitions, Bragg is focused on becoming a leader within the evolving global gaming industry.
Aveda energy investor presentation january 2014AvedaEnergy
Aveda is a growing provider of specialized oilfield hauling and rentals in North America. It provides services such as rig moving, heavy hauling, and hot shot services. The company also rents equipment like matting, tanks, and light towers. Aveda recently acquired an oilfield rental business and plans to acquire M&K, expanding its operations. It aims to benefit from organic and acquisition growth opportunities across the continent.
Hexo and Redecan 2021 investor deck - 7.7.2021Hexo Corp
HEXO Corp. has entered into an agreement to acquire Redecan, which would make HEXO the largest licensed cannabis producer in Canada. The transaction would combine HEXO's and Redecan's brands and product portfolios to provide leadership across major Canadian markets and product categories. The acquisition is expected to improve HEXO's profitability and accelerate its path to earnings per share growth. Synergies between the companies' production capabilities, brands, and distribution networks are expected to generate cost savings and revenue opportunities.
DSS Inc. (NYSE American: DSS) is a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. DSS is led by its seasoned leaders with decades of industry experience.
- Catasys provides an integrated virtual healthcare program called OnTrak that uses predictive analytics and outreach to identify and enroll high-cost members with behavioral health issues.
- OnTrak provides a 52-week treatment program that combines medical, pharmacological and psychosocial treatments to reduce costs by an average of 50% for enrolled members.
- Catasys has national agreements with several leading health plans covering over 7.5 million lives and is currently enrolling participants in 18 states.
Aveda energy investor presentation july 2014 finalAvedaEnergy
Aveda is a growing provider of specialized oilfield hauling and rentals in North America. This corporate presentation outlines Aveda's operations, recent acquisitions, management team, capitalization, balance sheet, and North American footprint. It also provides an overview of Aveda's oilfield hauling and rentals divisions, including recent fleet expansions and a case study demonstrating Aveda's performance advantages over competitors.
The document provides an overview of Nobilis Health Corp., including its business model, growth strategy, and the healthcare industry landscape. Nobilis owns and operates ambulatory surgical centers and specialty hospitals across multiple states. It utilizes a direct-to-consumer marketing model to drive organic patient volume growth. Nobilis' growth strategy focuses on acquiring additional facilities, optimizing its service lines and case mix, and leveraging operational efficiencies. The healthcare industry is shifting procedures to lower-cost outpatient settings like ASCs, which provides opportunities for Nobilis to expand.
- Therapix Biosciences is a clinical-stage pharmaceutical company focusing on proprietary synthetic cannabinoid technologies for central nervous system indications.
- They are developing novel sublingual and nasal formulations of FDA-approved synthetic THC (dronabinol) for indications like Tourette Syndrome and Mild Cognitive Impairment.
- For Tourette Syndrome, they are combining THC with PEA in a proprietary combination therapy called THX-TS01 that has begun Phase II clinical trials based on a 505(b)(2) regulatory pathway.
- For Mild Cognitive Impairment, they are developing an "Ultra-Low Dose THC" therapy called THX-ULD
This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination
between Bespoke Capital Acquisition Corp. (“BCAC”) and Vintage Wine Estates, Inc. (“VWE”) and related transactions (collectively the “Potential Transactions".
The document is a corporate presentation from Zenabis Global Inc. that provides disclaimers about the information contained within, noting that it does not constitute an offer or investment advice, contains forward-looking statements, and historical performance should not be relied upon as indicative of future results. The presentation includes information about the company, its facilities, production capacity, proposed regulatory changes, market trends, and competitive environment, but cautions that all forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Recipients are advised to not rely on the information for investment decisions and to consider the company's other public disclosures.
Max Healthcare Institute Limited's investor presentation provides an overview of the company and its growth drivers. It highlights the following key points in 3 sentences:
Max Healthcare is India's second largest hospital chain in terms of revenue, EBITDA and market capitalization, with a dominant presence in the largest and most profitable markets of Delhi NCR and Mumbai. It has a vision to be the most well regarded healthcare provider in India committed to clinical excellence, cutting edge technology, and research. The presentation outlines Max Healthcare's track record, strategic focus areas, and financial performance to position it for continued strong growth and profitable expansion.
The document is a corporate presentation for Zenabis Global Inc. that provides an overview of the company's history and operations. It notes that Zenabis was formed in January 2019 through the reverse takeover of Bevo Agro Inc. by Sun Pharm Investments Ltd. Bevo Agro had a successful 30+ year history of growing hundreds of unique crops at an industrial scale in British Columbia, with EBITDA growing at 20% annually from 2011 to 2018 and EBITDA margins of around 24% in 2018. The presentation contains standard disclaimer language about forward-looking statements and the purpose of the document being for information only.
We’re creating better everyday products that combine cutting-edge plant-based materials and the latest sustainable designs so you can look good AND feel good!
Aveda Transportation and Energy Services Inc. presented its corporate strategy and outlook in January 2017. The presentation discussed Aveda's history of growth through acquisitions and expansion across North America since 1994. It highlighted Aveda's leadership team and board of directors with extensive oilfield experience. The presentation also noted Aveda's track record of revenue and adjusted EBITDA growth despite a 40% decline in rig counts from 2015 to 2016, demonstrating resilience in the downturn.
Corporate presentation november 2016 finalcorpaveda2015
This corporate presentation provides an overview of Aveda Transportation and Energy Services Inc. It discusses Aveda's history of growth through acquisitions and expansion across North America. The presentation highlights Aveda's diversified revenue base across major oil basins in the US and Canada, as well as its blue chip customer base. It also summarizes Aveda's capitalization, balance sheet, and North American operations footprint.
This document contains an investor presentation for an organization providing chronic pain services and medical cannabis telehealth. It discusses the company's growth from $600k in 2018 revenue to $12.6 million in 2020, its network of 9 pain clinics across Canada, and plans for expansion. It also outlines the company's proprietary digital platform, pharmacy initiatives including pharmacist education and patient referrals, and financial overview showing its sources of revenue. The document contains numerous disclaimers regarding forward-looking statements and risks involved in the company's projections.
The Health & Wellness market in the UK was valued at £23bn in 2020, an increase from £20.5bn in 2015. Total healthcare, wellness and fitness spending in the UK reached £209bn in 2020. Pure Restore Health provides innovative treatments and therapies utilizing the latest healthcare technologies to help people feel their best by addressing issues like chronic pain, injury recovery, athletic performance and more.
Marel held a Capital Markets Day to provide an overview of the company and its strategy for delivering 12% annual revenue growth globally through digital and sustainable solutions. Marel aims to be a one-stop-shop across poultry, meat, and fish processing with standardized modular equipment, proprietary software, and digital solutions. The company's focus on innovation, excellence, and ESG/sustainability has supported over 20% average annual revenue growth since its 1992 listing.
This document provides an overview of Nobilis Health Corp., including:
- Nobilis operates surgical hospitals, ambulatory surgery centers (ASCs), and clinics across multiple states, utilizing a direct-to-consumer marketing model.
- Their growth strategy focuses on optimizing their case mix, acquiring additional facilities and service lines, and leveraging operational efficiencies through scale.
- Their unique marketing approach drives organic patient volume growth by targeting prospective patients and providing a superior experience for physicians and patients.
Marel Capital Markets Day 2021 - DigitalizationMarel
The document provides an overview of a presentation by Marel hf. on digitally transforming food processing. It includes disclaimers that no representations or warranties are given, information is subject to change, and forward-looking statements involve risks. Market and industry data is from Marel's internal research and estimates and has not been verified. The presentation does not constitute an offer to purchase securities.
Marel Capital Markets Day 2021 - Global-reachMarel
The document provides an overview and disclaimer for a presentation by Marel hf. It states that the purpose is to provide information about the company and its disclaimer notes that no representations are made about the accuracy or completeness of the information. It also says the information is based on current matters and is subject to change without notice. Finally, it notes the presentation does not constitute an offer to purchase securities and is not intended as investment advice.
Bragg Gaming Group is a next generation gaming group with cutting-edge technology, leading brands and world-class management expertise, developing into a global gaming force. Formed by a team of gaming industry experts, Bragg's main portfolio asset is ORYX Gaming, an innovative business-to-business gaming technology platform and casino content aggregator. Through this brand and targeted acquisitions, Bragg is focused on becoming a leader within the evolving global gaming industry.
Aveda energy investor presentation january 2014AvedaEnergy
Aveda is a growing provider of specialized oilfield hauling and rentals in North America. It provides services such as rig moving, heavy hauling, and hot shot services. The company also rents equipment like matting, tanks, and light towers. Aveda recently acquired an oilfield rental business and plans to acquire M&K, expanding its operations. It aims to benefit from organic and acquisition growth opportunities across the continent.
Hexo and Redecan 2021 investor deck - 7.7.2021Hexo Corp
HEXO Corp. has entered into an agreement to acquire Redecan, which would make HEXO the largest licensed cannabis producer in Canada. The transaction would combine HEXO's and Redecan's brands and product portfolios to provide leadership across major Canadian markets and product categories. The acquisition is expected to improve HEXO's profitability and accelerate its path to earnings per share growth. Synergies between the companies' production capabilities, brands, and distribution networks are expected to generate cost savings and revenue opportunities.
DSS Inc. (NYSE American: DSS) is a multinational company operating business segments in blockchain security, direct marketing, healthcare, consumer packaging, real estate, renewable energy, and securitized digital assets. Its business model is based on a distribution sharing system in which shareholders will receive shares in its subsidiaries as DSS strategically spins them out into IPOs. DSS is led by its seasoned leaders with decades of industry experience.
- Catasys provides an integrated virtual healthcare program called OnTrak that uses predictive analytics and outreach to identify and enroll high-cost members with behavioral health issues.
- OnTrak provides a 52-week treatment program that combines medical, pharmacological and psychosocial treatments to reduce costs by an average of 50% for enrolled members.
- Catasys has national agreements with several leading health plans covering over 7.5 million lives and is currently enrolling participants in 18 states.
Aveda energy investor presentation july 2014 finalAvedaEnergy
Aveda is a growing provider of specialized oilfield hauling and rentals in North America. This corporate presentation outlines Aveda's operations, recent acquisitions, management team, capitalization, balance sheet, and North American footprint. It also provides an overview of Aveda's oilfield hauling and rentals divisions, including recent fleet expansions and a case study demonstrating Aveda's performance advantages over competitors.
The document provides an overview of Nobilis Health Corp., including its business model, growth strategy, and the healthcare industry landscape. Nobilis owns and operates ambulatory surgical centers and specialty hospitals across multiple states. It utilizes a direct-to-consumer marketing model to drive organic patient volume growth. Nobilis' growth strategy focuses on acquiring additional facilities, optimizing its service lines and case mix, and leveraging operational efficiencies. The healthcare industry is shifting procedures to lower-cost outpatient settings like ASCs, which provides opportunities for Nobilis to expand.
- Therapix Biosciences is a clinical-stage pharmaceutical company focusing on proprietary synthetic cannabinoid technologies for central nervous system indications.
- They are developing novel sublingual and nasal formulations of FDA-approved synthetic THC (dronabinol) for indications like Tourette Syndrome and Mild Cognitive Impairment.
- For Tourette Syndrome, they are combining THC with PEA in a proprietary combination therapy called THX-TS01 that has begun Phase II clinical trials based on a 505(b)(2) regulatory pathway.
- For Mild Cognitive Impairment, they are developing an "Ultra-Low Dose THC" therapy called THX-ULD
This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination
between Bespoke Capital Acquisition Corp. (“BCAC”) and Vintage Wine Estates, Inc. (“VWE”) and related transactions (collectively the “Potential Transactions".
The document is a corporate presentation from Zenabis Global Inc. that provides disclaimers about the information contained within, noting that it does not constitute an offer or investment advice, contains forward-looking statements, and historical performance should not be relied upon as indicative of future results. The presentation includes information about the company, its facilities, production capacity, proposed regulatory changes, market trends, and competitive environment, but cautions that all forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Recipients are advised to not rely on the information for investment decisions and to consider the company's other public disclosures.
Max Healthcare Institute Limited's investor presentation provides an overview of the company and its growth drivers. It highlights the following key points in 3 sentences:
Max Healthcare is India's second largest hospital chain in terms of revenue, EBITDA and market capitalization, with a dominant presence in the largest and most profitable markets of Delhi NCR and Mumbai. It has a vision to be the most well regarded healthcare provider in India committed to clinical excellence, cutting edge technology, and research. The presentation outlines Max Healthcare's track record, strategic focus areas, and financial performance to position it for continued strong growth and profitable expansion.
The document discusses plans for a luxury customization brand called Hadoro. It summarizes that Hadoro had strong growth from €1.4M in 2017 to €9M in 2019 and plans to reach €21.5M in 2020. It outlines Hadoro's strategy to become a leader in new material development and launch a unique retail concept called Hadoro Lab for customizing accessories and watches. It also discusses plans to expand custom phone and watch offerings and create a full lifestyle collection through collaborations. Recent retail successes at Harrods and Galeries Lafayette Doha are cited in support of further retail development.
Hemptown Spring 2019 Investor PresentationHemptown USA
From the rich soils of Southern Oregon's Emerald Triangle, Hemptown USA is producing some of the finest cannabinoid products in the world.
Hemptown USA’s toolkit is a unique one. Combined with our vertically integrated business model we are in firmly positioned to capitalize on a global market expected to exceed $22 billion by 2020.
Inspirato is a luxury travel subscription company that provides access to over 600 luxury vacation homes and hotels. The company was founded in 2011 and has grown to over 25,000 subscribers. Inspirato utilizes proprietary technology to offer subscribers flexible travel with no nightly rates or taxes. The company aims to deliver exceptional luxury travel experiences through superior service and certainty.
Natco Pharma Limited is an integrated pharmaceutical company with operations across India, the US, and rest of world. It has a strong brand presence in oncology in India and is growing its portfolio in cardiology and diabetes. The company focuses on complex generics for the US market through niche Paragraph IV and Paragraph III filings. It has two R&D centers with over 525 employees and is poised for growth in the agricultural chemicals space. For the financial year ending March 2021, Natco Pharma reported total revenues of INR 21,557 million.
Liberty Health Sciences Inc. is a Florida-based producer and retailer of medical cannabis products with over 300 employees. They operate a 190,000 square foot cultivation facility and have 26 dispensaries across the state. In their July 2020 investor presentation, Liberty highlighted their strong revenue growth, becoming profitable in August 2019, and plans for expansion of cultivation, manufacturing, and retail operations to capitalize on the large and growing medical cannabis market in Florida.
BuildDirect's Q2 2022 investor presentation highlights a decrease in revenue and gross profit compared to the previous quarter, largely due to slowing customer demand, while adjusted EBITDA grew significantly. The presentation emphasizes BuildDirect's strategy of focusing on professional customers through acquisitions that expand its product assortment and customer base. It also discusses risks associated with suppliers, competition, and attracting and retaining customers.
This document summarizes an investor presentation for MedReleaf Corp.'s initial public offering. Key points include that MedReleaf is seeking to raise approximately $100 million Canadian dollars in an IPO priced between $9.50-$10.50 per share. Proceeds will be used to expand MedReleaf's existing cannabis production and manufacturing facilities, fund clinical research, and for general working capital purposes. The presentation highlights MedReleaf's current operational success and leadership in the Canadian medical cannabis market.
This document summarizes an investor presentation for MedReleaf Corp.'s initial public offering. It outlines key details of the offering such as the issuer, selling shareholders, offering price range between $9.50-$10.50 per share, expected size of $100 million, and intended use of proceeds. It also highlights MedReleaf's leadership in the Canadian medical cannabis market through its high quality indoor cultivation facilities, low production costs, revenue growth while maintaining profitability, and plans for expansion.
Nextdoor is a hyperlocal social networking app that connects neighborhoods.
The San Francisco-based company was founded in 2010 by social media veterans Sarah Leary, Nirav Tolia, Prakash Janakiraman & David Wiesen, and funded by Benchmark Capital and Shasta Ventures.
Nextdoor went public in November 2021 through a merger with a Khosla Ventures-backed SPAC in a deal that reportedly values the company at $4.3 billion
Read more: https://bestpitchdeck.com/nextdoor
Pathway Health is an integrated healthcare company that provides advanced products and services to patients suffering from chronic pain and related conditions. The Company owns and operates nine community-based clinics across four provinces where its team of health professionals work together to help patients through a variety of evidence-based approaches and products, including medical cannabis. Pathway's patient care programs utilize an interdisciplinary approach that is guided by trained pain specialists, physical and occupational therapists, psychologists, nurses, and other healthcare providers. Pathway is also the leading provider of medical cannabis services in Canada and has established itself as the collaboration partner with national and regional pharmacy companies for the delivery of medical cannabis services to their customers. The Company is working with several pharmacy companies on the development of Cannabis Health Products (CHPs) for OTC distribution through retail pharmacy locations across the country following anticipated changes to the Cannabis Act.
Canadian Overseas Petroleum Limited is an international oil and gas exploration, development, and production company actively pursuing opportunities in the United States and in sub-Saharan Africa through its ShoreCan joint venture company in Nigeria, and independently in other countries.
COPL’s acquisition of Atomic Oil and Gas LLC and its affiliate companies in December 2020 has had a transformational impact on the group and is significantly value-enhancing. It provides an immediate and growing revenue stream and underpins the group’s strategic objectives.
We have a team of individuals who have many years of relevant industry experience and who possess a strong track record of making discoveries and bringing those to production. Our goal is to continue to expand our company by developing existing assets and securing discoveries. We specialize in exploiting oil assets in lightly explored emerging regions where large discoveries occur. We achieve this by focusing on single well-unappraised discoveries in these basins and evaluating them and bringing them into production quickly and efficiently.
COPL has a strong balance sheet, secure cash flow, and is now well placed to deliver increased production and enhanced revenues, profitability, and shareholder value.
Liberty Health Sciences Inc. is a vertically integrated cannabis producer and retailer operating in Florida with over 300 employees, 26 dispensaries, 190,000 square feet of cultivation space, and has been profitable since August 2019. The document provides an overview of Liberty's operations, production capacity, product offerings, retail footprint in Florida, and financial information including quarterly revenue figures showing steady growth since Q3 2019.
Canadian Overseas Petroleum Limited: Investor Presentation - October 2022 CHF Investor Relations
COPL is an international oil and gas exploration, development and production
company actively pursuing opportunities in the United States with operations in
Converse County Wyoming, and in sub-Saharan Africa through its ShoreCan joint
venture company in Nigeria, and independently in other countries.
The Company’s Wyoming operations are one of the most environmentally responsible
with minimal gas flaring and methane emissions combined with electricity sourced
from a neighbouring wind farm to power production facilities.
Liberty Health Sciences Investor Relations Deck for FY2021-August. For more information on our company and products, please visit us at www.libertyhealthsciences.com.
Apollo Hospitals Enterprise Limited is a leading private healthcare services provider in India with over 6 decades of operations. It operates 71 hospitals with close to 10,000 beds across India and has expanded access to affordable healthcare through various initiatives. Apollo has played a pivotal role in developing the private healthcare sector in India by improving clinical outcomes and attracting medical talent both from India and overseas. Going forward, the company aims to continue its growth through a focus on clinical excellence, digital healthcare, and expansion into underserved markets.
DeFi Technologies builds and manages assets in the rapidly emerging decentralized financial market, providing institutional and retail investors easy access to previously unseen returns through innovative projects and groundbreaking protocols that are fundamentally reshaping the global financial system.
Pathway Health is one of the largest providers of out-of-hospital pain management services in . The Company owns and operates 9 community-based clinics across 4 provinces where its team of health professionals work together to help patients through a variety of evidence-based approaches. Pathway Health's patient care programs utilize an interdisciplinary approach that is guided by trained pain specialists, physical and occupational therapists, psychologists, nurses, and other healthcare providers. Pathway Health has also developed an expertise in harm reduction where medicinal cannabis is being used as an alternative to traditional opioids.
Similar to Canni med investor presentation june 2017 (20)
Cleades Robinson, a respected leader in Philadelphia's police force, is known for his diplomatic and tactful approach, fostering a strong community rapport.
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
The E-Way Bill revolutionizes logistics by digitizing the documentation of goods transport, ensuring transparency, tax compliance, and streamlined processes. This mandatory, electronic system reduces delays, enhances accountability, and combats tax evasion, benefiting businesses and authorities alike. Embrace the E-Way Bill for efficient, reliable transportation operations.
Methanex is the world's largest producer and supplier of methanol. We create value through our leadership in the global production, marketing and delivery of methanol to customers. View our latest Investor Presentation for more details.
ZKsync airdrop of 3.6 billion ZK tokens is scheduled by ZKsync for next week.pdfSOFTTECHHUB
The world of blockchain and decentralized technologies is about to witness a groundbreaking event. ZKsync, the pioneering Ethereum Layer 2 network, has announced the highly anticipated airdrop of its native token, ZK. This move marks a significant milestone in the protocol's journey, empowering the community to take the reins and shape the future of this revolutionary ecosystem.
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4
World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4World economy charts case study presented by a Big 4study presented by a Big 4
2. DISCLAIMER
GENERAL
This documentation is a presentation of general background information about the activities of CanniMed Therapeutics Inc. (the “Company”, “CMED”, “us” or “we”). The information contained in this presentation is derived
solely from otherwise publicly available information concerning CMED and does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an
investment in CMED.
This presentation does not constitute or form part of any offer or invitation for the sale or purchase of securities or any of the assets, business or undertaking described herein nor shall it or any part of it form the basis of
or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this presentation who are considering acquiring securities of CMED are reminded that
any such purchase or subscription must not be made on the basis of the information contained in this presentation but are referred to the continuous disclosure documents of CMED filed on SEDAR at www.sedar.com.
The contents of this presentation are not to be construed as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal,
financial or tax advice.
No representation or warranty, express or implied, is made or given by or on behalf of CMED or any of its affiliates or subsidiary undertakings or any of the directors, officers or employees of any such entities as to the
accuracy, completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any person for such information or opinions. In furnishing this presentation,
CMED does not undertake or agree to any obligation to provide the attendees with access to any additional information or to update this presentation or to correct any inaccuracies in, or omissions from, this presentation
that may become apparent. No person has been authorised to give any information or make any representations other than those contained in this presentation and, if given and/or made, such information or
representations must not be relied upon as having been so authorised. The information and opinions contained in this presentation are provided as at the date of this presentation.
In this presentation, all amounts are in Canadian dollars, unless otherwise indicated. Any graphs, tables or other information in this presentation demonstrating the historical performance of CMED or any other entity
contained in this presentation are intended only to illustrate past performance of such entities and are not necessarily indicative of future performance of CMED or such entities.
This presentation is being supplied to you solely for your information and may not be reproduced, further distributed or published in whole or in part by any other person. Distribution of this presentation may be restricted
or prohibited by law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and CMED does not accept liability to any person in relation thereto.
FORWARD-LOOKING INFORMATION
This presentation contains “forward-looking information” within the meaning of applicable securities laws in Canada. Forward-looking information may relate to our future outlook and anticipated events or results and
may include information regarding our financial position, business strategy, growth strategies, budgets, operations, financial results, taxes, dividend policy, plans and objectives. Particularly, information regarding our
expectations of future results, performance, achievements, prospects or opportunities or the markets in which we operates is forward-looking information. In some cases, forward-looking information can be identified by
the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “an opportunity exists”, “outlook”, “prospects”, “strategy”, “intends”, “believes”, or variations of such words and phrases or
state that certain actions, events or results “may”, “could”, “would”, “might”, “will”, “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, intentions, projections or other
characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations,
estimates and projections regarding future events or circumstances.
Forward-looking information contained in this presentation and other forward-looking information are based on our opinions, estimates and assumptions in light of our experience and perception of historical trends,
current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-
looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct.
Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information in this presentation, there may be other risk factors
not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this
presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should
not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this presentation represents our expectations as of the date of this
presentation or the date indicated, regardless of the time of delivery of the presentation. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a
result of new information, future events or otherwise, except as required under applicable securities laws in Canada. All of the forward-looking information contained in this presentation is expressly qualified by the
foregoing cautionary statements.
NON-IFRS MEASURES AND INDUSTRY METRICS
This presentation makes reference to certain non-IFRS measures including “EBITDA” and “Adjusted EBITDA”, and to certain operating metrics in the industry. Non-IFRS measures including industry metrics do not have a
standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement
those IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of
our financial information reported under IFRS. Please refer to the Prospectus for further details on these non-IFRS measures including industry metrics, including relevant definitions and reconciliations.
2
3. SUMMARY OVERVIEW
CanniMed Therapeutics Inc.
3
An international, biopharmaceutical company and
a leader in the Canadian cannabis industry with
best-in-class pharmaceutical-grade cannabis
products and a first mover advantage in rapidly
emerging international markets
4. Experienced LP with a 15 year history of growing medical cannabis
INVESTOR HIGHLIGHTS
Pharmaceutical
-Grade; GMP-
compliant;
investing in
clinical trials
The Canadian
medical market is
First mover
Strong management
and board
with broad experience in
cannabis, medical biotechnology,
and pharmaceuticals
4
Significant
Revenue, EBITDA
and Volume
Growth
to address the massive
advantage and
best positioned
international
market opportunity
here and now
with growing acceptance;
increasing evidence of
effectiveness; Baby Boomers are
a significant market opportunity
5. Recent
Developments
Strong 1H 2017
results
KG SOLD
(+77.2% H/H)
ADJUSTED EBITDA
(+$1.2MM H/H)
REVENUE
(+78.1% H/H)
Entered into Canada’s First Exclusive
Pharmacy Distribution Agreement for
Medical Cannabis
Commenced $10.5MM Cannabis Oils
Facility Expansion with Support of the
Saskatchewan Provincial Government
Agreement with CTT Pharmaceutical
Holdings Inc. (“CTT”) to License its Orally
Dissolvable Thin Film Wafer
5
Completed oils exports to Australia and
Cayman Islands and received follow-up
order for 360,000 ml of CanniMed® oils
to Australia
6. Pharmaceutical Cannabis
6
THE OPPORTUNITY IS SIGNIFICANT
Increased risk
of addiction,
overdose and
mortality
A strong need
for alternative
methods for pain
management
Seeking pain relief
and maintaining an
active lifestyle and
manage end-of-life
conditions
Legislative, political
environments are
more favorable
towards medical
cannabis globally
Commonly
prescribed opioids
Increasing
healthcare costs
Rapidly aging
population
Canada
is a leader
7. Here and Now
7
THE CANADIAN MEDICAL MARKET
2015 Q1 16 Q2 16 Q3 16
6,704
584
8,807
11,473
14,373
2,084
4,504
Herbal (kg)
Q/Q growth in
Registered Patients
32%
8% Q/Q growth
in Herbal
70% Q/Q growth in Oil
Cannabis oils have greatly accelerated market growth
7
Cannabis Oil (kg)
(1) Rolling 12 months. Shown as at the end of the reporting period. Includes wholesale sales.
Q4 16
14,373
17,026
8,613
8. BABY BOOMERS
To Provide a Step-Change in Demand
8
(1) Pain Resource Centre, 2015: Pain in Canada Fact Sheet (2) Canadian Pain Society. (3) Direct costs. Pain Resource Centre, 2015: Pain in Canada Fact Sheet. (4) The Canadian
Pain Society, 2011: Call to Action: The Need for a National Pain Strategy for Canada. (5) Globe and Mail, October 2014. (6) Canadian Centre on Substance Abuse, July 2015.
$2
$193
2015
2010
21.7
2015
2010
1 in 5
Canadian
adults suffer
from chronic
pain(2)
Chronic
pain costs
more than
$6 billion
annually(3)
Inadequate pain
assessment and
treatment is a
growing problem
in Canada(4)
Opioids are
prescribed for
chronic pain
despite little
evidence of long
term efficacy(5)
With an aging
population, the
incidence of
chronic pain
increases(1)
29%of the Canadian
population
16% of seniors use opioids(6)
New delivery mechanisms such
as cannabis oils and gelcaps are
ideally suited:
• More traditional forms
• Easier to target symptoms/doses
• Avoid stigmas associated
with smoking
9. INTERNATIONAL MARKETS
Opportunities are Exploding
9
International markets are opening very quickly
for pharma-quality products
9
Cayman Islands
Fulfilled order of
12,960ml of Oils to
the Cayman Islands
United States
Ownership of GMP
compliant production facility
with potential to support
over 50,000kg of capacity
per annum
In process of applying
to the DEA for a licence
DEA to allow for increased
supply for research purposes
Australia
Completed the first ever
shipment of commercial
cannabis oil and received
three subsequent orders for
360,000ml of Oil products
Worldwide population of baby
boomers is over 1.1 billion
~121.4 Million
Europe
baby boomers
~73.8 Million
U.S
baby boomers
~5.0 Million
Australia
baby boomers
European Union
Entered into a LOI with Creso Pharma Ltd.
for the purpose of marketing CMED
Medical Cannabis Brands
10. GMP Compliant
Extensive quality
control
Precision growing
and extraction
No pesticides
CanniMed is focused on
producing high-quality
products that are best
positioned in any market
Well Positioned for
the near and long term
10
CANNIMED THERAPEUTICS
(1) GMP are standards and procedures that pharmaceutical
companies must adhere to in manufacturing their products in North
America; part of quality assurance that ensures that drugs are
consistently produced and controlled to meet quality standards
FRAMEWORK STILL TBD
Recreational
Medical
Product
will be key
differentiation
CMED
Provide significant opportunity
best-in-class oils
– particularly in consumables
High margin
New delivery mechanisms
provide opportunities for IP
distributionPharmacy
will be a game changer
to international markets
Only pathway
OPPORTUNITY IS NOW
11. Herbal
CANNIMED PRODUCT OFFERING
Pharmaceutical-quality and branding
promotes doctor confidence and supports
more effective prescription dosages
Identified by the
percentage of THC
and CBD they
contain
Each product is designed with
specific benefits in mind to
address each patient’s
requirements
Purple 1·13
0.7% THC
13.0% CBD
Red 4·10
4.0% THC
10.0% CBD
Orange 9·9
9.0% THC
9.5% CBD
Yellow 12·0
12.5% THC
<0.5% CBD
Green 15·5
15.0% THC
5.0% CBD
Blue 17·1
17.0% THC
0.7% CBD
Indigo 22·1
22.0% THC
0.7% CBD
11
12. Oils
CANNIMED PRODUCT OFFERING
For patients reluctant to smoke herbal product
• Ideal for palliative care and hospitalized patients
• Significant sales acceleration since launching oils in Q1 2016
For baby boomers looking for a safe,
reliable way to manage their chronic pain
symptoms and maintain an active lifestyle
PRODUCTION Ramp 2H 2017CANNABIS OILS
Higher margin, value-added products with
Purple 1·20
0.7
20.0
60
THC mg/ml
CBD mg/ml
THC mg
TOTAL CBD mg1,200
Orange 10·10
9.8
9.9
588
TOTAL CBD mg594
THC mg/ml
CBD mg/ml
THC mg
Blue 18·0
18.3
0.2
1,098
12
THC mg/ml
CBD mg/ml
THC mg
TOTAL CBD mg
12
global market appeal
GEL CAPS
13. adding 5,000 kg additional capacity in 2018
Saskatoon, Saskatchewan
13
GMP-COMPLIANT PRODUCTION FACILITIES
(1) Benefited from the technologies and innovations advanced over the course of seven distinct facility builds.
Good Production
Practices (GPP)
Required under ACMPR
International
Organization for
Standardization (ISO)
GMP Standards
Only LP deemed by Health
Canada to be compliant
Required for pharmaceutical
production
GMP
97,000 sq. ft.
above-ground production facility
30 large individual biosecure growth chambers
7,000 kg current capacity;
State-of-the-art, GMP-compliant
5 separate Level 7 “Seventh
Generation”
facility(1)
production process
MOST RIGOROUS
RIGOROUS
LEAST RIGOROUS
security compliant
vaults
Above ground facility on 100 acres,
currently using approximately 20 acres
14. Clinical Trials
1414
• “CAPRI Trial”(1)
- First Phase II Health Canada approved clinical
trial using cannabis ($1 million invested)
- Randomized, double-blind, placebo
controlled, proof-of-concept Phase IIA clinical
trial
- Seeks to examine the varying ratios of THC and
CBD in patients with osteoarthritis of the knee
• “Identifying the molecular mechanisms involved
in suppressing multiple sclerosis induced
neuropathic pain following cannabinoid
treatment in an animal model of multiple
sclerosis” the Company’s pre-clinical study
partnered with Dr. Namaka at the University of
Manitoba.
• “CARE-E Trial” in patients with refractory pediatric
epilepsy, partnered with Dr. Richard Huntsman at
the University of Saskatchewan.
• “PICATE Trial” in patients with Tourette’s
syndrome, partnered with Dr. Paul Sandor at
Toronto Western Hospital.
(1) Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of the Knee
Investing in Medical Care
15. Growing Momentum
REVENUE AND GROWTH
(1) Includes both dried herbal and oils1515
Total Dried Equivalents
(KG)(1)
Oil Equivalent
(KG)
341.3
403
229
714
49
% of Revenue
18.9% 45.1%
1H 2016 1H 2017H1 2016
Patients Physicians
25,991
10,224
2,385
H1 2017
3,840
16. s
Historical Financials
16
REVENUE AND GROWTH
(1) Financial results as of Q1 ending January 31, 2017; (2) Includes MMPR
Achieved
Aggressively expanding
infrastructure to meet
accelerating market demand
Total Revenue(1)(2) Oil Revenue (1)(2)
Experiencing
Rapid Sales
Growth
32%of kg Sold
in 1H 2017
Cannabis Oils
of $0.2MM in 1H 2017
positive adj. EBITDA Launching oils in Q1 2016 has accelerated
growth and expanded opportunities for
new customers
Introduction of pharmaceutical-grade
in Canada and internationally
gel caps anticipated to accelerate growth
2015
98.2% Margin
2016
83.7% Margin
LTM
80.7% Margin
1H 2016 1H 2017
$5.8 $5.7
$9.8
$8.2
$12.9
$8.9
$4.0 $3.5
$7.1
$4.1
17. Capitalization
REVENUE AND GROWTH
17 (1) As of close of June 12, 2017; shares outstanding as of Q2 Year-End: 22,670,933
OCTOBER 31, 2016
FISCAL YEAR-END ($M)
April 30, 2017
Q2 ($M)
CASH 2.0 59.0
TOTAL CURRENT ASSETS 14.7 72.1
CURRENT LIABILITIES 7.8 6.1
DEBT 29.6 17.7
SHAREHOLDERS EQUITY 10.6 91.8
CURRENT MARKET CAPITALIZATION
(June 12, 2017)
$196.8(1)
CURRENT ENTERPRISE VALUE $155.5(1)
18. Strong Management Team and Board
18
KEY MANAGEMENT
President & CEO
Brent H. Zettl
• President of CanniMed since 1991
• Spearheaded the development activities of the
innovative underground growth chambers
• 2014 E&Y Entrepreneur of the Year for the
Prairies Business-to-Consumer category
CFO
John Knowles
• Over 30 years experience in senior executive and
board roles in Canada and internationally
• A Director of CanniMed for over eight years and past
Chair of the Audit and Finance Board Committee
• Former VP, CFO of Hudbay Minerals Inc., Executive VP
of Aur Resources Inc., and CEO of LiCo Energy Metals
Inc.
Chief Research Officer
Larry Holbrook
• Background includes Senior Research Scientist
positions with extensive and diverse agricultural
biotechnology experience in both government
and industrial settings
• Over 20 years of experience in basic research and
applications to genetic modification of crop plants
• Author or co-author on 40 publications and books
VP, Business Development and Regulatory Affairs
Gulwant Bajwa
• Previously with Health Canada as a Senior Program
Manager in former Bureau of Medical Cannabis
and as a Policy Analyst in the Intellectual Property
and Technology Transfer office of Health Canada
• Five years as Director of Operations at JDS
Uniphase Corporation
19. Strong Management Team and Board
19
BOARD OF DIRECTORS
LL.B, B.A. (Chairman)
Donald Ching
Director, Golden Opportunities Fund;
Former President and CEO of SaskTel
Doug Banzet
CFO and Director, Golden
Opportunities Fund
B.B.A.
Rob Duguid
Partner, PFM Capital; VP, Prairie
Ventures Fund
Ph.D.
Marianne Greer
Independent Pharmacist Consultant
B.Sc.
Richard Hoyt
VP, Business Development,
Mallinckrodt PLC
B.Comm, C.P.A., C.A.
Dwayne L. Lashyn
VP, Quantico Capital Corp.
Ph.D., J.D.
Bruce F. Mackler
Consultant in FDA, USDA and EPA
Regulatory Processes
Ph.D.
Brandon J. Price
Executive VP, Nascent Biotech;
Co-founder, Biogenin
B.Comm, C.P.A., C.A.
John L. Knowles
CFO and Director,
CanniMed Therapeutics Inc.
Brent Zettl
President, CEO and Director,
CanniMed Therapeutics Inc.
B.S.AB.B.A.